CG Oncology (CGON) Free Cash Flow (2023 - 2026)
CG Oncology (CGON) posted Free Cash Flow of -$57.2 million for Q1 2026, down 57.99% on a QoQ basis from -$36.2 million in Q4 2025, and down 95.28% year-over-year from -$1.2 billion in Q1 2025.
CG Oncology (CGON) Free Cash Flow (2023 - 2026) Analysis & Trends
CG Oncology's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$57.2 million for Q1 2026.
- Quarterly Free Cash Flow fell 95.28% year-over-year to -$57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.3 million (down 95.03% YoY) and the FY2025 annual result came in at -$132.4 million, down 67.75% from the prior year.
- Free Cash Flow was -$57.2 million for Q1 2026 at CG Oncology, down from -$36.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.0 million in Q1 2023 and bottomed at -$57.2 million in Q1 2026.
- A 4-year average of -$24.2 million and a median of -$20.9 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow slumped 225.87% — and 2025, when it declined 12.56%.
- CG Oncology's Free Cash Flow stood at -$14.6 million in 2023, then plunged by 42.51% to -$20.9 million in 2024, then plunged by 73.48% to -$36.2 million in 2025, then plunged by 57.99% to -$57.2 million in 2026.
- Business Quant data shows CGON's Free Cash Flow at -$57.2 million in Q1 2026, -$36.2 million in Q4 2025, and -$39.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | CG Oncology | 6.01 Bn | 6.01 Bn | -1.88 Mn | -57.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.20 Mn |
| Mar 31, 2026 | -57.20 Mn |
| Dec 31, 2025 | -36.21 Mn |
| Dec 31, 2025 | -36.21 Mn |
| Sep 30, 2025 | -38.96 Mn |
| Sep 30, 2025 | -38.96 Mn |
| Jun 30, 2025 | -27.97 Mn |
| Jun 30, 2025 | -27.97 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Mar 31, 2025 | -29.29 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Dec 31, 2024 | -20.87 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Jun 30, 2024 | -16.13 Mn |
| Mar 31, 2024 | -26.02 Mn |
| Mar 31, 2024 | -26.02 Mn |
| Dec 31, 2023 | -14.65 Mn |
| Dec 31, 2023 | -14.65 Mn |